1Ginès P,Wong F,Watson H,et al.Effects of satavaptan a selective vasopressin V (2)receptor antagonist,on ascites and serum sodium in cirrhosis with hyponatremia:a randomized trial. Hepatology . 2008
5Bernardi M,Laffi G,Salvagnini M,et al.Effcacy and safety of the stepped care medical treatment of ascites in liver cirrhosis:a randomized controlled clinical trial comparing two diets with different sodium content. Liver . 1993
6Wong F,Blei AT,Blendis LM,et al.A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebocontrolled trial. Hepatology . 2003
7Ginès P,Wong F,Watson H,et al.Effects of satavaptan a selective vasopressin V (2)receptor antagonist,on ascites and serum sodium in cirrhosis with hyponatremia:a randomized trial. Hepatology . 2008
7Forman LM, Lueey MR. Predicting the prognosis of chronic liver disease:an evolution from child to meld mayo end- stage liver disease[ J]. Hepatology,2001 ;33:473-475.
8Bernardi M, Laffi G, Salvagnini M, et al. Effcacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content [J]. Liver, 1993 ;13 : 156-162.
9Abramham A. Jacob CK. Severe hypanatraemia current concepts on pathogenesis and treatment[J]. Natl Med India,2001 ; 14 : 277.
